Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Europe picks companies to help build Argonaut moon lander - 2One-third of asylum applications by Iranians approved in Germany
- 3Woman, 60, Is Finally Traveling the World Decades After Husband’s Death Held Her Back
- 4FDA updates risk classification for voluntary shredded cheese recall
- 5Floods, Landslides Triggered By Heavy Rain In Afghanistan Leave 77 Dead In 10 days, Authorities Say
- Exploring the Gig Economy: Illustrations from Consultants
- NASA will bring space station crew home early after medical issue
- Holden Commodore Turbo BT1 Police Interceptor Offered for Sale in Australia
- Most loved Fish Dish: What's Your Sea Pleasure?
- Kona SUV: The Courageous Minimized That is Catching Hearts Around the world
- Pilot captures jaw-dropping northern lights show from 36,000 feet (photos)
- Most normal matter in the universe isn't found in planets, stars or galaxies – an astronomer explains where it's distributed
- How to avoid or deal with an outrageous medical bill
- Iran war triggering Easter staycation boom
